BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16

• Press Releases

  Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

  July 13, 2026

   · 

  8 min read
• Press Releases

  New Phase 1 Data Show VNA-318 Mechanism of Action Translates to Humans, Supporting Potential to Address Medical Needs of People with Neurodegenerative Diseases

  July 13, 2026

   · 

  4 min read
• Press Releases

  Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline

  July 13, 2026

   · 

  6 min read
• Press Releases

  INDIANA UNIVERSITY AND PHARMATROPHIX PRESENT FINDINGS ON PERFORMANCE OF ORAL THERAPEUTIC, LM11A-31, TO REDUCE DECLINE OF BRAIN FUNCTIONAL-NETWORK CONNECTIVITY IN ALZHEIMER’S DISEASE

  July 13, 2026

   · 

  6 min read
• Press Releases

  Genethon’s Recent Accomplishments Underscore the Progress of Genetic Medicine from Scientific Promise to Clinical Reality

  July 13, 2026

   · 

  2 min read
• Press Releases

  Bora Biologics Expands U.S. Commercial Manufacturing Platform with Addition of Rockville Site

  July 13, 2026

   · 

  3 min read
• Press Releases

  NeuroTherapia to Present Phase 2a Alzheimer’s Disease Clinical Data at the AAIC 2026 Conference in London, UK

  July 13, 2026

   · 

  4 min read
• Press Releases

  Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

  July 13, 2026

   · 

  15 min read
• 

  Complete response letters

  FDA posts new rejection letters days after confirming pause

  The FDA last week confirmed that it would suspend the release of complete response letters pending the resolution of a citizen petition from an unnamed pharma company. Nevertheless, 14 new CRLs are now available on the agency’s portal.

  July 13, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  AB Science ends 3 studies in multiple sclerosis, other immune conditions

  The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of prioritization, not safety, the biotech said.

  July 13, 2026

   · 

  2 min read

   · 

  Tristan Manalac